NTx Welcomes Accomplished Healthcare Industry Executive Dr. James Coffin as New CEO

0
114
Dr. James Coffin

RIO RANCHO, N.M.– NTx (Nature’s Toolbox), a life sciences company enabling novel pharmaceutical RNA and protein development and production, today announced that it has appointed Jamie Coffin, Ph.D., as its new CEO. Dr. Coffin has over 20 years of leadership experience within the healthcare and life sciences sector. His experience building powerful teams and leading multi-billion-dollar companies in the healthcare technology space will be invaluable as NTx focuses on commercializing its in-vitro products and developing new partnerships.

Earlier in his career, Dr. Coffin led the global, multi-billion-dollar healthcare and life sciences businesses at both Dell and IBM Healthcare. Most recently, he served as the President and Chief Operating Officer of Sema4, a health information company providing advanced genomic testing. During his tenure at Sema4, he grew the company’s revenue from less than $50M to over $200M and built up the team from under 300 to over 1000 people in less than four years.

“NTx’s novel technology has the potential to transform the way modern therapeutics are developed and accessed around the world,” said Dr. Jamie Coffin, CEO of NTx. “I am excited to be on board and look forward to building on the already stellar team and expanding the company’s global footprint through strategic business and clinical partnerships.”

Alex Koglin, Ph.D., NTx’s co-founder, will serve as President and Chief Science Officer and as a member of the Board of Directors to drive continued R&D and manufacturing efforts and ensure technical readiness as the company heads toward larger scale production and commercialization.

“Jamie is an experienced and highly skilled leader who brings proven expertise from some of the world’s largest healthcare technology companies,” said Dr. Alex Koglin, President, CSO and co-founder of NTx. “I look forward to working alongside him and the rest of our team to advance NTx into a worldwide operation that enables more equal and expedited access to life-changing therapeutics for all people.”